

Charles M Rudin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/97800/publications.pdf>

Version: 2024-02-01

383
papers

57,707
citations

1793

106
h-index

1410

227
g-index

402
all docs

402
docs citations

402
times ranked

59161
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585.	7.7	48
2	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100256.	0.6	4
3	Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. <i>Cancer Research</i> , 2022, 82, 472-483.	0.4	18
4	Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1401-1407.	2.8	21
5	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. <i>Clinical Cancer Research</i> , 2022, 28, 1391-1401.	3.2	19
6	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
7	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
8	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
9	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, 2144.	5.8	18
10	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	1.1	10
11	Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e325-e329.	1.1	3
12	Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2938-2952.	3.2	11
13	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. <i>Cell Reports</i> , 2022, 39, 110814.	2.9	43
14	POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1109-1121.	0.5	29
15	Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers. <i>Cancer Research</i> , 2022, 82, 6238-6238.	0.4	1
16	Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
17	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1014-1031.	0.5	31
18	Delta-like ligand 3â€‘targeted radioimmunotherapy for neuroendocrine prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17

#	ARTICLE	IF	CITATIONS
19	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3797-3803.	3.2	15
20	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	7.7	14
21	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. <i>Clinical Cancer Research</i> , 2022, 28, 4702-4713.	3.2	25
22	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
23	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 532-541.	3.2	19
24	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010.	3.2	15
25	<i>MET</i> Exon 14 "altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	3.2	35
26	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 240-244.	7.7	10
27	TMEM41B Is a Pan-flavivirus Host Factor. <i>Cell</i> , 2021, 184, 133-148.e20.	13.5	127
28	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C "Mutant Non" Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215.	3.2	65
29	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	3.2	20
30	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42
31	Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. <i>Bioconjugate Chemistry</i> , 2021, 32, 1255-1262.	1.8	7
32	Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, 237-246.	1.6	2
33	N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. <i>Viruses</i> , 2021, 13, 769.	1.5	6
34	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 503-514.	5.7	72
35	Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. <i>Genes and Development</i> , 2021, 35, 870-887.	2.7	6
36	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	7.7	66

#	ARTICLE	IF	CITATIONS
37	An optimized NGS sample preparation protocol for inÂvitro CRISPR screens. STAR Protocols, 2021, 2, 100390.	0.5	2
38	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	5.8	68
39	Abstract LB186: MAPK pathway activation represents a therapeutic vulnerability inASCL1-driven SCLC. , 2021, , .		0
40	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TÂcell immunity. Cancer Cell, 2021, 39, 973-988.e9.	7.7	93
41	Quantitative <i>In Vivo</i> Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. Cancer Research, 2021, 81, 4570-4580.	0.4	13
42	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Antiâ€PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	7.7	222
43	<i>Rlfâ€Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 3214-3229.	7.7	24
44	Co-targeting TGF-Î² and PD-L1 with radiation therapy: The Goldilocks principle. Cell Reports Medicine, 2021, 2, 100406.	3.3	1
45	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
46	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell, 2021, 39, 1245-1261.e6.	7.7	58
47	Small-cell lung cancer. Nature Reviews Disease Primers, 2021, 7, 3.	18.1	560
48	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 2021, 39, 1479-1496.e18.	7.7	155
49	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology and Oncology, 2021, 14, 170.	6.9	26
50	A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. Viruses, 2021, 13, 2113.	1.5	10
51	MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. IScience, 2021, 24, 103224.	1.9	13
52	Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 419-432.	1.2	55
53	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	0.5	172
54	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiotherapy and Oncology, 2020, 144, 101-104.	0.3	21

#	ARTICLE	IF	CITATIONS
55	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	0.5	234
56	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444.	2.9	118
57	CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. <i>Frontiers in Oncology</i> , 2020, 10, 1387.	1.3	247
58	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13.	7.7	210
59	Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2020, 26, 5424-5437.	3.2	21
60	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1522-1534.	0.5	12
61	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	3.2	133
62	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	13.5	691
63	Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12957-12977.	2.9	48
64	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1871-1879.	0.5	24
65	Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2175-2185.	1.9	8
66	CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	1.5	14
67	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	5.8	31
68	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	0.8	410
69	Lineage plasticity in cancer: a shared pathway of therapeutic resistance. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 360-371.	12.5	263
70	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. <i>Clinical Cancer Research</i> , 2020, 26, 147-158.	3.2	59
71	Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. <i>Nature Cancer</i> , 2020, 1, 359-369.	5.7	25
72	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290.	13.7	213

#	ARTICLE	IF	CITATIONS
73	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	0.5	119
74	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. <i>Nature Medicine</i> , 2020, 26, 259-269.	15.2	274
75	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020, 25, 140-149.	1.9	38
76	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802.	3.2	8
77	Clinical outcomes, local/regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
78	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
79	HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	7.7	149
80	SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. <i>Lung Cancer</i> , 2020, 145, 126-131.	0.9	12
81	Targeted Therapies and Biomarkers in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 741.	1.3	65
82	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	3.2	257
83	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	0.5	232
84	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. <i>Acta Oncologica</i> , 2019, 58, 1634-1639.	0.8	10
85	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
86	Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1122-1124.	0.5	0
87	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924.	3.2	200
88	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1583-1593.	0.5	55
89	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	3.2	206
90	Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. <i>Nature Cell Biology</i> , 2019, 21, 1403-1412.	4.6	254

#	ARTICLE	IF	CITATIONS
91	Frequency and outcomes of brain metastases in patients with <i>HER2</i> -mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387.	2.0	51
92	Positron-Emission Tomographic Imaging of a Fluorine 18- ¹⁸ F-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1743-1752.	0.5	14
93	Afatinib in patients with metastatic or recurrent <i>HER2</i> -mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	1.3	69
94	Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. <i>Science Signaling</i> , 2019, 12, .	1.6	130
95	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019, 10, 278.	5.8	143
96	Immunophenotype and Response to Immunotherapy of <i>RET</i> -Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	73
97	Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in <i>EGFR</i> -Mutated Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	35
98	Acquired <i>BRAF</i> Rearrangements Induce Secondary Resistance to <i>EGFR</i> therapy in <i>EGFR</i> -Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019, 14, 802-815.	0.5	71
99	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722.	3.2	292
100	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. <i>Annals of Oncology</i> , 2019, 30, 597-603.	0.6	114
101	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. <i>Modern Pathology</i> , 2019, 32, 1106-1122.	2.9	58
102	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019, 19, 289-297.	12.8	692
103	Epigenetic targeting of DNA repair in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22429-22431.	3.3	5
104	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	15.2	485
105	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	26
106	Targeting the EMT transcription factor <i>TWIST1</i> overcomes resistance to <i>EGFR</i> inhibitors in <i>EGFR</i> -mutant non-small-cell lung cancer. <i>Oncogene</i> , 2019, 38, 656-670.	2.6	140
107	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
108	Activation of <i>KRAS</i> Mediates Resistance to Targeted Therapy in <i>MET</i> Exon 14-mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1248-1260.	3.2	92

#	ARTICLE	IF	CITATIONS
109	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	3.0	96
110	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	3.9	94
111	Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	7.7	149
112	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
113	Target engagement imaging of PARP inhibitors in small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 176.	5.8	75
114	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
115	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. <i>Modern Pathology</i> , 2018, 31, 111-121.	2.9	50
116	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	3.2	85
117	Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i> -Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	60
118	Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	0.8	381
119	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
120	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	0.8	276
121	P1.01-76 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, S492.	0.5	0
122	MA19.09 Concurrent Mutations in <i>STK11</i> and <i>KEAP1</i> is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB. <i>Journal of Thoracic Oncology</i> , 2018, 13, S424.	0.5	28
123	MA22.01 PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency. <i>Journal of Thoracic Oncology</i> , 2018, 13, S433.	0.5	0
124	NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. <i>Science</i> , 2018, 362, 1416-1422.	6.0	267
125	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. <i>Annals of Oncology</i> , 2018, 29, 2085-2091.	0.6	221
126	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108

#	ARTICLE	IF	CITATIONS
127	Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. <i>Clinical Cancer Research</i> , 2018, 24, 5143-5152.	3.2	63
128	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099.	1.6	258
129	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8581-TPS8581.	0.8	22
130	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017, 31, 286-299.	7.7	370
131	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>Loss</i> “Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704.	1.9	31
132	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3931-3941.	0.4	91
133	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51.	5.1	412
134	Unravelling the biology of SCLC: implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 549-561.	12.5	336
135	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
136	P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1302-S1303.	0.5	12
137	OA05.03 Single-Agent Rovalpituzumab Tesirine, a Δ -Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S260-S261.	0.5	1
138	MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S406-S407.	0.5	12
139	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
140	Histone Code Aberrancies in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 599-601.	0.5	2
141	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
142	Shining light on novel targets and therapies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 75-76.	12.5	50
143	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. <i>Nature Medicine</i> , 2017, 23, 1362-1368.	15.2	462
144	Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 548-554.	0.6	36

#	ARTICLE	IF	CITATIONS
145	A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1764-1776.	1.5	61
146	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
147	Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. <i>Radiotherapy and Oncology</i> , 2017, 125, 130-135.	0.3	37
148	A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-III A resectable NSCLC. <i>EJNMMI Research</i> , 2017, 7, 8.	1.1	16
149	Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. <i>Annals of Oncology</i> , 2017, 28, 278-284.	0.6	43
150	Phase 2 Study of Erlotinib in Combination With Avelinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	1.1	29
151	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535.	3.2	252
152	Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. <i>Radiology</i> , 2017, 282, 251-258.	3.6	25
153	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	0.8	829
154	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , 2017, 2017, 1-5.	0.6	20
155	KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC). <i>Annals of Oncology</i> , 2017, 28, v541.	0.6	6
156	Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. <i>Journal of Clinical Investigation</i> , 2017, 127, 2957-2967.	3.9	58
157	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479.	0.7	11
158	Small-cell lung cancer in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2017, 6, S67-S70.	1.3	5
159	Abstract CT115: Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients. <i>Cancer Research</i> , 2017, 77, CT115-CT115.	0.4	13
160	Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 8510-8510.	0.8	16
161	PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 8512-8512.	0.8	33
162	Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 9012-9012.	0.8	37

#	ARTICLE	IF	CITATIONS
163	Molecular determinants of response and resistance to anti-PD-(L)1 blockade in patients with NSCLC profiled with targeted next-generation sequencing (NGS).. Journal of Clinical Oncology, 2017, 35, 9015-9015.	0.8	4
164	STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 9016-9016.	0.8	15
165	Afatinib in patients with metastatic <i>HER2</i> -mutant lung cancers: An international multicenter study.. Journal of Clinical Oncology, 2017, 35, 9071-9071.	0.8	14
166	Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, TPS3108-TPS3108.	0.8	12
167	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.. Journal of Clinical Oncology, 2017, 35, TPS8575-TPS8575.	0.8	7
168	Lung cancers with mutations in <i>EGFR</i> exon 18: Molecular characterization and clinical outcomes in response to tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2017, 35, 9029-9029.	0.8	0
169	Liquid biopsy in the clinic: A prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy.. Journal of Clinical Oncology, 2017, 35, 11536-11536.	0.8	0
170	In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.. Journal of Clinical Oncology, 2017, 35, e23150-e23150.	0.8	0
171	Abstract 1727: Circulating Tumor Cells (CTCs) in patients with extensive stage small cell lung cancer and their association with clinical outcome. , 2017, , .		0
172	CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. Journal of Clinical Investigation, 2016, 126, 2610-2620.	3.9	336
173	Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. PLoS ONE, 2016, 11, e0160587.	1.1	49
174	Missing the mark in <i>FGFR1</i> -amplified squamous cell cancer of the lung. Cancer, 2016, 122, 2938-2940.	2.0	8
175	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer, 2016, 122, 2371-2378.	2.0	57
176	ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC. Journal of Thoracic Oncology, 2016, 11, S252-S253.	0.5	14
177	PS01.24: Clinical Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma Characterized by Next-Generation Sequencing. Journal of Thoracic Oncology, 2016, 11, S283.	0.5	1
178	SLFN11 Is Necessary for Single Agent Sensitivity to Talazoparib, a Potent PARP Inhibitor, But Not for Radiosensitization in Small Cell Lung Cancer (SCLC) Cell Lines and Patient-Derived Xenografts (PDX). International Journal of Radiation Oncology Biology Physics, 2016, 96, S75.	0.4	0
179	P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine, 2016, 8, 345ra87.	5.8	152
180	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	5.1	365

#	ARTICLE	IF	CITATIONS
181	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
182	A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 23-30.	0.9	57
183	A combinatorial strategy for treating KRAS-mutant lung cancer. <i>Nature</i> , 2016, 534, 647-651.	13.7	337
184	Preclinical oncology "reporting transparency needed. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 8-9.	12.5	1
185	Medians and Milestones in Describing the Path to Cancer Cures. <i>JAMA Oncology</i> , 2016, 2, 167.	3.4	40
186	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	1.1	116
187	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Oncology Practice</i> , 2016, 12, 83-86.	2.5	32
188	Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2897-2907.	3.2	48
189	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156
190	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-like Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	3.2	342
191	A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2 nd or 3 rd -line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8512-8512.	0.8	14
192	Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8564-8564.	0.8	6
193	<i>MDM2</i> amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced <i>RET</i> -rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9068-9068.	0.8	15
194	Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA8505-LBA8505.	0.8	13
195	A phase I trial of certolizumab plus chemotherapy in patients with stage IV lung adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9080-9080.	0.8	0
196	Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9084-9084.	0.8	0
197	Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8541-8541.	0.8	0
198	Abstract 3756: PARP inhibitor sensitivity in small cell lung cancer cell lines and patient-derived xenografts correlates with SLFN11 expression but not with structural homologous recombination deficiency. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract 4356: Identification of the anthrax toxin receptor (ANTXR1) as the high affinity cellular receptor for Seneca Valley Virus (SVV). , 2016, , .		0
200	Abstract 4187: Loss of SLFN11 or gain of TWIST1 promote chemotherapy resistance in small cell lung cancer. , 2016, , .		1
201	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports, 2015, 13, 2159-2173.	2.9	51
202	Phase I trial of Seneca Valley Virus (NTXâ€œ10) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 743-750.	0.8	63
203	Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget, 2015, 6, 56-70.	0.8	27
204	Hedgehog Signaling Pathway Is Active in GBM with GLI1 mRNA Expression Showing a Single Continuous Distribution Rather than Discrete High/Low Clusters. PLoS ONE, 2015, 10, e0116390.	1.1	27
205	Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. PLoS ONE, 2015, 10, e0129103.	1.1	7
206	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	5.8	498
207	Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology, 2015, 72, 1021-1026.e8.	0.6	176
208	Small cell lung cancer: Where do we go from here?. Cancer, 2015, 121, 664-672.	2.0	459
209	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	9.4	434
210	Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 2015, 17, 545-554.	0.6	78
211	Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor. Molecular Cancer Therapeutics, 2015, 14, 3-13.	1.9	78
212	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncology, 2015, 51, 383-388.	0.8	74
213	Genomic Analysis of Smoothed Inhibitor Resistance in Basal Cell Carcinoma. Cancer Cell, 2015, 27, 327-341.	7.7	316
214	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping. Cancer Discovery, 2015, 5, 842-849.	7.7	514
215	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. Clinical Cancer Research, 2015, 21, 2244-2255.	3.2	179
216	DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene, 2015, 34, 5869-5878.	2.6	195

#	ARTICLE	IF	CITATIONS
217	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
218	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
219	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. <i>Journal of Clinical Oncology</i> , 2015, 33, 2877-2884.	0.8	181
220	A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. <i>Science Translational Medicine</i> , 2015, 7, 302ra136.	5.8	436
221	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 4106-4111.	0.8	265
222	Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 8007-8007.	0.8	15
223	A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 8017-8017.	0.8	6
224	Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping. <i>Journal of Clinical Oncology</i> , 2015, 33, 8021-8021.	0.8	7
225	Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS). <i>Journal of Clinical Oncology</i> , 2015, 33, 7518-7518.	0.8	1
226	Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer. , 2015, , .		1
227	Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies. , 2015, , .		0
228	Abstract LB-286: The patient-derived xenograft mouse model dilemma; a new solution for an old problem. , 2015, , .		0
229	Abstract 610: Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing. , 2015, , .		0
230	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E748-57.	3.3	90
231	Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. <i>Cancer Medicine</i> , 2014, 3, 1322-1335.	1.3	24
232	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
233	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1669-1674.	0.5	106
234	RET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1240-1242.	0.5	11

#	ARTICLE	IF	CITATIONS
235	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1031-1035.	0.5	44
236	A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277.	0.5	33
237	Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). <i>Ecological Management and Restoration</i> , 2014, 27, 757-763.	0.2	86
238	Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer. <i>American Journal of Medicine</i> , 2014, 127, 443-449.	0.6	48
239	MYC, MAX, and Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 273-274.	7.7	11
240	Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 2846-2856.	0.4	52
241	SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. <i>Lung Cancer</i> , 2014, 85, 1-6.	0.9	28
242	Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 414-418.	0.5	33
243	Prospective Molecular Evaluation of Small Cell Lung Cancer (Sclc) Utilizing the Comprehensive Mutation Analysis Program (Map) at Memorial Sloan Kettering Cancer Center (Mskcc). <i>Annals of Oncology</i> , 2014, 25, iv511.	0.6	6
244	Abstract A12: Screening for TWIST1 inhibitors as a novel therapy for oncogene-driven lung cancer.. <i>Clinical Cancer Research</i> , 2014, 20, A12-A12.	3.2	1
245	Abstract IA03: Genomic and epigenomic targets in small cell lung cancer.. <i>Clinical Cancer Research</i> , 2014, 20, IA03-IA03.	3.2	1
246	Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7602-7602.	0.8	4
247	Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9012-9012.	0.8	4
248	Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung: Clinicopathologic features, treatment, and survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19046-e19046.	0.8	1
249	Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer. , 2014, , .		0
250	Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC. , 2014, , .		0
251	Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. <i>Molecular Cancer</i> , 2013, 12, 16.	7.9	42
252	Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 2584-2591.	3.2	134

#	ARTICLE	IF	CITATIONS
253	Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers. International Journal of Radiation Oncology Biology Physics, 2013, 86, 143-149.	0.4	37
254	The future of epigenetic therapy in solid tumours—lessons from the past. Nature Reviews Clinical Oncology, 2013, 10, 256-266.	12.5	299
255	Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothed Antagonists. Cancer Cell, 2013, 23, 23-34.	7.7	296
256	Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opinion on Biological Therapy, 2013, 13, 1273-1285.	1.4	58
257	Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 619-623.	0.5	119
258	The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 1387-1400.	1.5	79
259	Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1059-1065.	3.0	106
260	ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2013, 12, 1131-1139.	1.9	33
261	Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Research, 2013, 19, 2766-2774.	3.2	147
262	Poly(β -amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer <i>In Vitro</i> and <i>In Vivo</i> . Molecular Cancer Therapeutics, 2013, 12, 405-415.	1.9	40
263	Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer. Molecular Cancer Research, 2013, 11, 329-338.	1.5	54
264	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer, 2013, 109, 1085-1092.	2.9	54
265	Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e41-e42.	0.5	93
266	Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 78-98.	2.3	331
267	Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy.., 2013, , .		1
268	Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e295-e300.	1.8	8
269	Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG Tj ETQq1 1 0.7848 14 rgBT5/Overlock	0.7848	14
270	Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2013, 31, 8009-8009.	0.8	81

#	ARTICLE	IF	CITATIONS
271	Alterations of immune response of non-small cell lung cancer with Azacytidine. <i>Oncotarget</i> , 2013, 4, 2067-2079.	0.8	336
272	Abstract B45: The Twist box domain is required for Twist1-induced metastasis of prostate cancer cells. , 2013, , .		0
273	Abstract 5644: Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to vismodegib.. , 2013, , .		0
274	Abstract 5675: Optimization of a Seneca Valley Virus (SVV) 3C protease substrate for virus-directed enzyme prodrug therapy.. , 2013, , .		0
275	Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e295-e300.	1.8	1
276	Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2171-2179.	13.9	1,201
277	Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis. <i>PLoS Genetics</i> , 2012, 8, e1002650.	1.5	86
278	Vismodegib. <i>Clinical Cancer Research</i> , 2012, 18, 3218-3222.	3.2	95
279	Therapeutic potential of Hedgehog signaling inhibitors in cancer: rationale and clinical data. <i>Clinical Investigation</i> , 2012, 2, 371-385.	0.0	1
280	Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. <i>Journal of General Virology</i> , 2012, 93, 2606-2613.	1.3	24
281	Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived. <i>Current Problems in Cancer</i> , 2012, 36, 156-173.	1.0	6
282	Crizotinib in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1195-1201.	0.9	73
283	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1111-1116.	9.4	906
284	A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothed Antagonists. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 165-173.	1.9	77
285	Cigarette smoking and lung cancerâ€™ relative risk estimates for the major histological types from a pooled analysis of caseâ€™control studies. <i>International Journal of Cancer</i> , 2012, 131, 1210-1219.	2.3	390
286	Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3163-3169.	3.2	470
287	PX-866 and docetaxel in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3024-3024.	0.8	4
288	Esophageal cancer gender disparity.. <i>Journal of Clinical Oncology</i> , 2012, 30, 47-47.	0.8	3

#	ARTICLE	IF	CITATIONS
289	Abstract 1802: IGF-1R inhibition as a novel therapeutic strategy for small cell lung cancer. , 2012, , .		0
290	Abstract 2954: TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer. , 2012, , .		0
291	Abstract 2049: Preclinical profile of AMG900 in combination with HDACi in prostate cancer. , 2012, , .		0
292	Esophageal cancer incidence gender disparity.. Journal of Clinical Oncology, 2012, 30, 1573-1573.	0.8	1
293	A phase II study of obatoclox mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer, 2011, 74, 481-485.	0.9	84
294	Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology, 2011, 29, 909-916.	0.8	498
295	Itraconazole Side Chain Analogues: Structure-Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog Signaling. Journal of Medicinal Chemistry, 2011, 54, 7363-7374.	2.9	45
296	A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1757-1760.	0.5	138
297	Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1086-1113.	2.3	29
298	DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature, 2011, 471, 325-330.	18.7	573
299	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2011, 17, 2502-2511.	3.2	499
300	Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1075-1082.	0.8	49
301	Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research, 2011, 17, 2512-2520.	3.2	112
302	Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features. Clinical Cancer Research, 2011, 17, 888-895.	3.2	129
303	Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biology and Therapy, 2011, 12, 617-628.	1.5	29
304	Notch Signaling Contributes to Lung Cancer Clonogenic Capacity <i>In Vitro</i> but May Be Circumvented in Tumorigenesis <i>In Vivo</i> . Molecular Cancer Research, 2011, 9, 1746-1754.	1.5	38
305	Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer. Cancer Research, 2011, 71, 6764-6772.	0.4	132
306	Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer. Cancer Discovery, 2011, 1, 598-607.	7.7	596

#	ARTICLE	IF	CITATIONS
307	Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs. Cancer Research, 2011, 71, 2557-2557.	0.4	2
308	Abstract 5209: The roles of Notch signaling in the development of non-small cell lung cancer. , 2011, , .		1
309	Abstract 3271: Inhibition of angiogenesis and tumor growth by itraconazole in primary xenograft models of human non-small cell lung cancer. , 2011, , .		0
310	Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts. , 2011, , .		0
311	Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer. , 2011, , .		0
312	A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2010, 66, 1079-1085.	1.1	69
313	Geographic Proximity and Racial Disparities in Cancer Clinical Trial Participation. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1343-1351.	2.3	27
314	The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. Clinical Cancer Research, 2010, 16, 5997-6003.	3.2	38
315	Beyond the Scalpel: Targeting Hedgehog in Skin Cancer Prevention. Cancer Prevention Research, 2010, 3, 1-3.	0.7	13
316	Skin Deep and Deeper: Multiple Pathways in Basal Cell Carcinogenesis. Cancer Prevention Research, 2010, 3, 1213-1216.	0.7	5
317	Abstract 3738: Exploratory patient (pt) stratification markers associated with sensitivity to ABT-263 in small cell lung cancer (SCLC). , 2010, , .		0
318	Determinants of Apoptotic Sensitivity to HSP90 Inhibition In Acute Myeloid Leukemia. Blood, 2010, 116, 2159-2159.	0.6	0
319	Youth has no age: cancer treatment for older Americans. Oncology, 2010, 24, 1114, 1118, 1120.	0.4	0
320	Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies. Oncologist, 2009, 14, 119-124.	1.9	19
321	<i>Smoothened</i> Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science, 2009, 326, 572-574.	6.0	774
322	Lung Cancer in Never Smokers: A Call to Action: Fig. 1.. Clinical Cancer Research, 2009, 15, 5622-5625.	3.2	33
323	Upregulation of <i>MMP-2</i> by HMGA1 Promotes Transformation in Undifferentiated, Large-Cell Lung Cancer. Molecular Cancer Research, 2009, 7, 1803-1812.	1.5	71
324	Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research, 2009, 15, 5646-5661.	3.2	137

#	ARTICLE	IF	CITATIONS
325	Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors. <i>Clinical Cancer Research</i> , 2009, 15, 5626-5645.	3.2	433
326	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 264-270.	0.8	55
327	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2009, 361, 1164-1172.	13.9	1,054
328	Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. <i>New England Journal of Medicine</i> , 2009, 361, 1173-1178.	13.9	951
329	A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture <i>in vitro</i> . <i>Cancer Research</i> , 2009, 69, 3364-3373.	0.4	406
330	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. <i>Blood</i> , 2009, 113, 2014-2021.	0.6	189
331	Randomized Phase II Study of Carboplatin and Etoposide With or Without the <i>bcl-2</i> Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103. <i>Journal of Clinical Oncology</i> , 2008, 26, 870-876.	0.8	158
332	Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. <i>Journal of Clinical Oncology</i> , 2008, 26, 1119-1127.	0.8	207
333	Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 2321-2328.	0.4	187
334	Novel Systemic Therapies for Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 315-322.	2.3	23
335	Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 59-67.	0.5	6
336	Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. <i>Cancer Research</i> , 2008, 68, LB-138-LB-138.	0.4	8
337	Management of small-cell lung cancer: incremental changes but hope for the future. <i>Oncology</i> , 2008, 22, 1486-92.	0.4	56
338	SVF1 Regulates Cell Survival by Affecting Sphingolipid Metabolism in <i>Saccharomyces cerevisiae</i> . <i>Genetics</i> , 2007, 175, 65-76.	1.2	18
339	Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1623-1633.	3.0	196
340	A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 638-644.	0.5	11
341	Fast, hungry and unstable: finding the Achillesâ€™ heel of small-cell lung cancer. <i>Trends in Molecular Medicine</i> , 2007, 13, 150-157.	3.5	29
342	P2-175: Phase 1/2 trial of ABT-751 in combination with pemetrexed vs pemetrexed alone in subjects with advanced or metastatic non-small-cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S639.	0.5	0

#	ARTICLE	IF	CITATIONS
343	DNA cleavage and Trp53 differentially affect SINE transcription. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 248-260.	1.5	14
344	Phase II study of PKC- δ antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 52, 173-180.	0.9	33
345	A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2006, 54, 69-77.	0.9	40
346	Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 245-251.	0.5	22
347	Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.. <i>Clinical Cancer Research</i> , 2006, 12, 1251-1259.	3.2	88
348	Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 64-72.	0.4	163
349	Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in <i>Saccharomyces cerevisiae</i> . <i>Yeast</i> , 2005, 22, 641-652.	0.8	27
350	Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate. <i>Molecular Cancer Research</i> , 2005, 3, 635-644.	1.5	18
351	Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1110-1117.	0.8	171
352	A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 915-920.	0.6	32
353	Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 7244-7251.	3.2	95
354	Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan. <i>Journal of Clinical Oncology</i> , 2004, 22, 1382-1388.	0.8	927
355	Akt Stimulates Aerobic Glycolysis in Cancer Cells. <i>Cancer Research</i> , 2004, 64, 3892-3899.	0.4	1,297
356	Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1605-13.	1.9	79
357	Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. <i>Virology</i> , 2003, 313, 147-157.	1.1	103
358	Bcl-xL and Akt cooperate to promote leukemogenesis in vivo. <i>Oncogene</i> , 2003, 22, 688-698.	2.6	32
359	Human Alu element retrotransposition induced by genotoxic stress. <i>Nature Genetics</i> , 2003, 35, 219-220.	9.4	126
360	A phase II study of bryostatatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 191-196.	0.9	40

#	ARTICLE	IF	CITATIONS
361	An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4546-4552.	0.8	135
362	Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. <i>Cancer Research</i> , 2003, 63, 312-8.	0.4	130
363	Bcl-x Complements <i>Saccharomyces cerevisiae</i> Genes That Facilitate the Switch from Glycolytic to Oxidative Metabolism. <i>Journal of Biological Chemistry</i> , 2002, 277, 44870-44876.	1.6	59
364	A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. <i>Annals of Oncology</i> , 2002, 13, 539-545.	0.6	148
365	Phase I Study of Dose-Dense Alternating Doublets in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 3, 265-270.	1.1	2
366	Mobile Genetic Element Activation and Genotoxic Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2002, 2, 25-35.	3.3	38
367	Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. <i>Lung Cancer</i> , 2002, 38, 65-71.	0.9	16
368	Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1042-8.	3.2	44
369	Genotoxic exposure is associated with alterations in glucose uptake and metabolism. <i>Cancer Research</i> , 2002, 62, 3515-20.	0.4	54
370	Transcriptional activation of short interspersed elements by DNA-damaging agents. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 64-71.	1.5	127
371	A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. <i>Investigational New Drugs</i> , 2001, 19, 303-310.	1.2	20
372	A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2001, 19, 329-333.	1.2	20
373	Transcriptional activation of short interspersed elements by DNA-damaging agents. , 2001, 30, 64.		2
374	Transcriptional activation of short interspersed elements by DNA-damaging agents. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 64-71.	1.5	2
375	Cell line dependence of Bcl-2-induced alteration of glutathione handling. <i>Oncogene</i> , 2000, 19, 472-476.	2.6	37
376	A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 128-132.	1.1	15
377	Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. , 1999, 85, 164-170.		108
378	What Keeps a Resting T Cell Alive?. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1999, 64, 383-388.	2.0	5

#	ARTICLE	IF	CITATIONS
379	Signal transduction pathways that regulate cell survival and cell death. <i>Oncogene</i> , 1998, 17, 3207-3213.	2.6	169
380	APOPTOSIS AND DISEASE: Regulation and Clinical Relevance of Programmed Cell Death. <i>Annual Review of Medicine</i> , 1997, 48, 267-281.	5.0	335
381	Apoptotic signaling in lymphocytes. <i>Current Opinion in Hematology</i> , 1996, 3, 35-40.	1.2	9
382	A novel enhancer in the immunoglobulin lambda locus is duplicated and functionally independent of NF kappa B.. <i>Genes and Development</i> , 1990, 4, 978-992.	2.7	102
383	Inhibition of immunoglobulin gene rearrangement by the expression of a lambda 2 transgene.. <i>Journal of Experimental Medicine</i> , 1989, 169, 1911-1929.	4.2	47